Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.91 | N/A | -8.34% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.91 | N/A | -8.34% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed cautious optimism about future growth opportunities despite the current EPS miss. They emphasized their commitment to innovation and addressing market challenges.
Management highlighted ongoing research efforts and potential future product developments.
They acknowledged the challenges faced in the current market environment.
Moderna's earnings report showed a significant EPS miss, which typically raises concerns among investors. However, the stock reacted positively, increasing by 3.35%. This rise may indicate investor confidence in the company's long-term potential despite the short-term challenges reflected in the earnings.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WELLTOWER INC REIT
Feb 11, 2025